Medacta Group SA / Key word(s): Annual Results
Press Release - Ad-hoc announcement pursuant to Art. 53 LR
Medacta Group SA reports strong results: +20.4% revenue growth in 2022 and solid adjusted EBITDA margin at 27.6%
Francesco Siccardi, CEO of Medacta, commented: “Despite the ongoing challenging environment, Medacta delivered a strong 2022 performance. Our 20.4% revenue growth from 2021 along with our Adjusted EBITDA margin of 27.6% (28.1% in constant currency), shows that Medacta was able to adapt, delivering a strong top-line growth and a resilient margin level.
Looking ahead, while some macroeconomic challenges may persist in 2023, we remain positive and will continue to invest in our people, innovation and medical education to maintain this momentum of solid results.”
In 2022, we celebrated an important milestone by surpassing 1’500 employees at Group level and close to 200 new jobs were added across all geographies, including significant salesforce expansion. We also made significant strategic investments on our infrastructure, in particular on May 18, 2022, we opened the doors of our new offices in Rancate. With an expansion of 2’100 square meters supporting the creation of new jobs, the new building complements and
works in complete synergy with the Castel San Pietro headquarters: two hubs of cutting-edge technology which continue to innovate responsibly for the benefit of patients, medical professionals, healthcare systems and the local community.
Management made strategic investments in strengthening our supply chain by increasing surgical instrument sets and implant stock to serve new customers, to cope with possible shortages and capture market opportunities. Also, we projected two major plant expansions at our Swiss headquarters to support our future growth. In Castel San Pietro, the production area will be expanded by about 5’300 square meters, bringing the total area to 15’300 square meters, with an increase of more than 50 percent in total area. The current 12’000 square meters in Rancate will be further expanded with a new area of about 9’500 square meters, with an increase of almost 80% in operational space. In total, Medacta plants in Ticino are foreseen to cover more than 36’800 square meters. These expansions will allow a significant increase in manufacturing capacity while always maintaining a strong alignment with our corporate sustainability pillars.
Innovation continued through all business lines. In a world where technology advances very fast, MySolutions Personalized Ecosystem embodies our vision to never stop improving the experience for patients, surgeons, and care facilities.
Within our MySolutions Personalized Ecosystem, NextAR™ platforms have been launched globally including Japan in June 2022. In October 2022, the NextAR™ Spine application was awarded by the 2022 Spine Technology Award from Orthopedics This Week.
The NextAR™ platform is offered as a hardware system with limited capital investment and single-use instrumentation at a low cost per case and offers the ability to host software for multiple applications in both joint and spine. The platform represents an optimal solution worldwide and particularly for U.S. Ambulatory Surgery Centers (ASCs).
We continued our commitment to medical education of surgeons. Besides in-person scientific events, the M.O.R.E. in Touch program offered surgeons valuable online resources to deepen their knowledge and discover more about our solutions. We further expanded our network of reference center surgeons active worldwide across all our business lines.
Strong Growth in All Regions and Business Lines
In 2022, revenue increased 15.0% at constant currency and 20.4% on a reported currency over the prior year, at Euro 437.1 million, with positive contributions from all business lines and geographies. The growth was driven by significant customer acquisition, salesforce expansion and successful new product introduction.
Revenue in Europe registered an increase of 17.6% from 2021 and 34.4% from 2019 on a constant currency basis, to Euro 187.4 million. North America grew to Euro 136.8 million, or 11.5% from 2021 and 34.6% from 2019 on a constant currency basis. Revenue in Asia Pacific increased by 11.2% from 2021 and 43.2% from 2019 on a constant currency basis, to Euro 94.4 million. Revenue in RoW was Euro 18.6 million, a growth of 38.7% from 2021 and 48.9% from 2019 on a constant currency basis.
In terms of trend by business line, revenue from our Hip products increased to Euro 203.6 million, or 9.2% from 2021 and 21.1% from 2019 on a constant currency basis. Revenue from our Knee offerings was Euro 164.5 million, a growth of 18.4% from 2021 and 41.8% from 2019 on a constant currency basis. Our Extremities business line reported an increase in revenue of 38.8% from 2021 and 175.3% from 2019 on a constant currency basis, to Euro 27.5 million. Revenue from our Spine offering grew by 19.2% from 2021 and 64.4% from 2019 at constant currency, to Euro 41.5 million.
Gross Profit Performance
The Gross Profit was EUR 305.3 million compared to EUR 261.2 million in the previous year. The Gross Profit margin was equal to 69.8% compared to 71.9% in 2021. This change was primarily due to temporary geographic mix effects caused by hospital staffing shortages and
significant longer than expected COVID impacts that lowered the contribution of USA and Australia on total volumes. Also, we experienced negative impact from currency development and price erosion.
Adjusted EBITDA Margin
The Adjusted EBITDA amounted to EUR 120.4 million (EUR 107.1 million in 2021), corresponding to a margin of 27.6% (28.1% in constant currency) compared to 29.5% in 2021. The change of margin reflects primarily the reduction in gross profit, the negative currency development and inflationary pressure on transports and travels partially compensated by the leverage on fixed costs from higher sales volumes.
Adjusted EBIT Margin
The Adjusted EBIT amounted to EUR 68.9 million, 15.8% on revenues, compared to EUR 66.7 million, 18.4% on revenues, in 2021. The change of margin was due to the reduction of EBITDA and higher depreciation and amortization, primarily from investment in instruments, to sustain the growth and to cope with supply chain disruption, and from material R&D projects completed in 2021.
Profit for the period
The profit for the period was EUR 46.2 million, compared to EUR 51.5 million in 2021 which benefited from non-recurring positive effects on income taxes (approximately EUR 4.5 million) and lower financial costs (EUR 3.3 million).
Solid Balance Sheet
Medacta’s balance sheet remains robust, with total assets increasing to EUR 584.5 million and an equity ratio of 47.0% at the end of the reporting period (46.3% in 2021). The Adjusted Free Cash Flow generated in 2022 amounted to EUR 21.6 million (EUR 33.8 million in 2021), after significant investments in new instruments and in the development of new implants and surgical instruments to sustain the future growth of Medacta.
Proposal for distribution
The Board of Directors, after assessing the strong economic and financial results of the year, decided to reward our shareholders through a distribution. Our Board members are proposing to the Annual General Meeting the distribution of CHF 0.54 per share, half of it to be distributed as dividend out of available earnings and half of it to be distributed out of accumulated reserves from capital contribution.
We are targeting at constant currency revenue in the range of EUR 480 million to EUR 495 million and adjusted EBITDA margin largely in line with 2022, subject to any unforeseen events.
Medacta’s Annual Report 2022 can be downloaded via this link: https://www.medacta.com/EN/financial-reports
Forward Financial Calendar
Webcast Today at 3:00 pm (CET)
Medacta Group SA will present its Full Year 2022 Financial Results during a webcast today at 3:00 pm (CET). The results call will be headed by Francesco Siccardi (CEO) and Corrado Farsetta (CFO). The conference will be held in English.
Dial-in numbers for conference call function only:
CH: +41 225954727
DE: +49 6917415713
UK: +44 1 212818003
USA: +1 7187058794
ITA: +39 02 36213011
Medacta International SA
Giorgio Botta, Head of Investor Relations
Phone: +41 91 696 14 95
Medacta is an international company specializing in the design, production, and distribution of innovative orthopedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 50 countries.
This press release has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the press release does not purport to be comprehensive and is not to be taken as containing any securities advice, recommendation, offer or invitation to subscribe for, purchase or redeem any securities regarding Medacta. The information contained in the press release does not purport to be comprehensive. Please refer to the Medacta 2022 Annual Report available on our website at https://www.medacta.com/EN/investors.
This press release has been prepared by Medacta and includes forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions.
There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this press release. Important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.
1 Alternative Performance Measures
This press release contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Cash Flow”, “Net Debt” and “Leverage”. Reconciliation of these measures as well as "CORE" financial measures is provided in the “Alternative Performance Measures” (APM) section of our 2022 Annual Report. These Alternative Performance Measures (APM) should be regarded as complementary information to, and not as a substitute for, the IFRS beginning performance measures. For definitions of APM, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed "Alternative Performance Measures" of the 2022 Annual Report.
The 2022 Annual Report is available at https://www.medacta.com/EN/financial-reports.
End of Inside Information
|Company:||Medacta Group SA|
|6874 Castel San Pietro|
|Phone:||+41 91 696 6060|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1584863|
|End of Announcement||EQS News Service|
1584863 17-March-2023 CET/CEST